Previous Issue
Volume 6, October
 
 
siuj-logo

Journal Browser

Journal Browser

Soc. Int. Urol. J., Volume 6, Issue 6 (December 2025) – 1 article

Cover Story (view full-size image): Société Internationale d’Urologie Journal (SIUJ) is an international, peer-reviewed, open access journal that covers all aspects of urology and related fields. SIUJ is the official journal of the Société Internationale d’Urologie (SIU) and is published bimonthly online by MDPI (since Volume 5, Issue 1 - 2024).
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Select all
Export citation of selected articles as:
13 pages, 288 KB  
Review
SIU-ICUD: Clinical Application of Liquid and Tissue-Based Biomarkers in Prostate Cancer
by Tamás Fazekas, Pawel Rajwa, Renu S. Eapen and Derya Tilki
Soc. Int. Urol. J. 2025, 6(6), 68; https://doi.org/10.3390/siuj6060068 - 10 Dec 2025
Viewed by 75
Abstract
Several liquid-, and tissue-based markers are available to guide primary diagnosis-, active surveillance-, and treatment-related decision-making for patients with prostate cancer. Most of these tests can improve the balance of harms and benefits associated with early detection, and aid patient selection for treatment [...] Read more.
Several liquid-, and tissue-based markers are available to guide primary diagnosis-, active surveillance-, and treatment-related decision-making for patients with prostate cancer. Most of these tests can improve the balance of harms and benefits associated with early detection, and aid patient selection for treatment intensification. However, the costs of these tests can make their integration in routine clinical practice challenging. To date, prostate-specific antigen (PSA) is still one of the most well-known and widely utilized tumor markers worldwide, with a unique facility ranging from the diagnosis to the treatment-related follow-up of patients with prostate cancer. Future research efforts are needed to integrate biomarkers and novel imaging techniques, such as prostate magnetic resonance imaging, in the decision-making pathways. Despite the growing body of knowledge and evidence, considerable challenges remain in optimizing risk-stratification, improving patient selection and cost-efficacy in different prostate cancer (PCa)-related settings. Full article
Previous Issue
Back to TopTop